201 related articles for article (PubMed ID: 32674739)
1. Inhibition of Interleukin-1 in the Treatment of Selected Cardiovascular Complications.
Heydari FS; Zare S; Roohbakhsh A
Curr Rev Clin Exp Pharmacol; 2021; 16(3):219-227. PubMed ID: 32674739
[TBL] [Abstract][Full Text] [Related]
2. Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases.
Emmi G; Urban ML; Imazio M; Gattorno M; Maestroni S; Lopalco G; Cantarini L; Prisco D; Brucato A
Curr Cardiol Rep; 2018 Jun; 20(8):61. PubMed ID: 29904899
[TBL] [Abstract][Full Text] [Related]
3. Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders.
Arnold DD; Yalamanoglu A; Boyman O
Front Immunol; 2022; 13():888392. PubMed ID: 35874710
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease.
Abbate A; Toldo S; Marchetti C; Kron J; Van Tassell BW; Dinarello CA
Circ Res; 2020 Apr; 126(9):1260-1280. PubMed ID: 32324502
[TBL] [Abstract][Full Text] [Related]
5. Failure of anti Interleukin-1 β monoclonal antibody in the treatment of recurrent pericarditis in two children.
Signa S; D'Alessandro M; Consolini R; Miniaci A; Bustaffa M; Longo C; Tosca MA; Bizzi M; Caorsi R; Mendonça LO; Pession A; Ravelli A; Gattorno M
Pediatr Rheumatol Online J; 2020 Jun; 18(1):51. PubMed ID: 32546242
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Interleukin-1β by Canakinumab and Cardiovascular Outcomes in Patients With Chronic Kidney Disease.
Ridker PM; MacFadyen JG; Glynn RJ; Koenig W; Libby P; Everett BM; Lefkowitz M; Thuren T; Cornel JH
J Am Coll Cardiol; 2018 May; 71(21):2405-2414. PubMed ID: 29793629
[TBL] [Abstract][Full Text] [Related]
7. Treating inflammation by blocking interleukin-1 in humans.
Dinarello CA; van der Meer JW
Semin Immunol; 2013 Dec; 25(6):469-84. PubMed ID: 24275598
[TBL] [Abstract][Full Text] [Related]
8. Anti-interleukin-1 agents for pericarditis: a primer for cardiologists.
Imazio M; Lazaros G; Gattorno M; LeWinter M; Abbate A; Brucato A; Klein A
Eur Heart J; 2022 Aug; 43(31):2946-2957. PubMed ID: 34528670
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
Ridker PM; Thuren T; Zalewski A; Libby P
Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 1β: a proinflammatory target for preventing atherosclerotic heart disease.
McCarty S; Frishman W
Cardiol Rev; 2014; 22(4):176-81. PubMed ID: 24618930
[TBL] [Abstract][Full Text] [Related]
11. Rilonacept and Other Interleukin-1 Inhibitors in the Treatment of Recurrent Pericarditis.
Goel A; Bandyopadhyay D; Malik AH; Gupta R; Frishman WH; Aronow WS
Cardiol Rev; 2023 Jul-Aug 01; 31(4):225-229. PubMed ID: 36398320
[TBL] [Abstract][Full Text] [Related]
12. Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis.
Ridker PM
Circ Res; 2019 Feb; 124(3):437-450. PubMed ID: 30702995
[TBL] [Abstract][Full Text] [Related]
13. The Future of IL-1 Targeting in Kidney Disease.
Afsar B; Covic A; Ortiz A; Afsar RE; Kanbay M
Drugs; 2018 Jul; 78(11):1073-1083. PubMed ID: 29968152
[TBL] [Abstract][Full Text] [Related]
14. IL-1β blockade in periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome: case-based review.
Soylu A; Yıldız G; Torun Bayram M; Kavukçu S
Rheumatol Int; 2021 Jan; 41(1):183-188. PubMed ID: 31324971
[TBL] [Abstract][Full Text] [Related]
15. IL-1β Inhibition in Cardiovascular Complications Associated to Diabetes Mellitus.
Peiró C; Lorenzo Ó; Carraro R; Sánchez-Ferrer CF
Front Pharmacol; 2017; 8():363. PubMed ID: 28659798
[TBL] [Abstract][Full Text] [Related]
16. The inflammasome and IL-1β: implications for the treatment of inflammatory diseases.
Satoh T; Otsuka A; Contassot E; French LE
Immunotherapy; 2015; 7(3):243-54. PubMed ID: 25804477
[TBL] [Abstract][Full Text] [Related]
17. Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases.
Bettiol A; Lopalco G; Emmi G; Cantarini L; Urban ML; Vitale A; Denora N; Lopalco A; Cutrignelli A; Lopedota A; Venerito V; Fornaro M; Vannacci A; Rigante D; Cimaz R; Iannone F
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 30999610
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of interleukin-1β decreases aneurysm formation and progression in a novel model of thoracic aortic aneurysms.
Johnston WF; Salmon M; Pope NH; Meher A; Su G; Stone ML; Lu G; Owens GK; Upchurch GR; Ailawadi G
Circulation; 2014 Sep; 130(11 Suppl 1):S51-9. PubMed ID: 25200056
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-1 blockade in cardiovascular diseases: a clinical update.
Buckley LF; Abbate A
Eur Heart J; 2018 Jun; 39(22):2063-2069. PubMed ID: 29584915
[TBL] [Abstract][Full Text] [Related]
20. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease?
Picco P; Brisca G; Traverso F; Loy A; Gattorno M; Martini A
Arthritis Rheum; 2009 Jan; 60(1):264-8. PubMed ID: 19116906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
